Patient-assistance programs, which often are funded largely by drugmakers, have helped many Americans afford the medications they need. But these programs' ties to pharmaceutical companies carry a high cost for the healthcare system, critics say.
Health plan officials will gather in Washington amid ominous ambiguity about the future of the Affordable Care Act's private insurance expansion.
Mark Ganz, president and CEO of Cambia Health Solutions, a not-for-profit parent of 22 companies offering healthcare products and services, discusses how his companies are seeking to make healthcare more consumer-directed.
Health insurance lobbyists are sharpening their knives this week in preparation for the CMS' scheduled announcement of preliminary 2016 Medicare Advantage payment rates after the markets close Friday.
Even as value-based contracting proliferates, the financial incentives for hospitals and medical groups to eliminate waste and improve care have barely changed.
As insurers face growing criticism for giving consumers inaccurate information about their provider networks, some experts are asking whether it's really that hard to maintain an accurate provider directory.
Insurers are under fire for giving consumers bad information about which providers are in their plan network. The controversy raises a simple question: Is it really so hard to maintain an accurate provider directory?
Eric Schultz, CEO of Wellesley, Mass.-based Harvard Pilgrim Health Care, discusses his organization's experience with the Obamacare insurance exchanges, narrow provider networks, re-entering the Medicare Advantage program, and his views on the expansion of Partners HealthCare in Massachusetts.
How much does it cost to get a drug approved? A new estimate puts the number at $2.55 billion, more than twice the cost assessed by the same lead researcher a decade ago. Not everyone believes the math.
A big fight could be brewing over Obamacare's risk-corridor program. Insurers are relying on the program to protect them from major losses if their exchange customers end up being sicker and more costly than anticipated. But Republicans—most notably Sen. Marco Rubio (R-Fla.), a likely 2016...
A second potential blockbuster drug from Gilead Sciences to treat hepatitis C has been approved by the FDA. But at a cost of nearly $100,000 for a full course of treatment, it is certain to spark further debate over the pricing of specialty drugs.
On the eve of the 2015 open enrollment period for Medicare beneficiaries, insurance leaders will gather in Washington to discuss public healthcare programs.